Acute respiratory distress syndrome

Summary

Acute respiratory distress syndrome (MONDO:0006502) is a disease with 5 cohort genes (8 GWAS associations across 6 studies) and 1,068 clinical trials. Top therapeutic interventions include cisatracurium, nitric oxide, and dexmedetomidine.

At a glance

• Cohort genes: 5
• GWAS associations: 8
• Clinical trials: 1,068

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	acute respiratory distress syndrome
Mondo ID	MONDO:0006502
EFO	EFO:1000637
ICD-10-CM	J80
ICD-11	1189702844
NCIT	C3353
UMLS	C2887484
MedGen	1812214
MedDRA	10001052
Is cancer (heuristic)	no

Also known as: acute lung injury · acute respiratory distress syndrome · ALI · ARDS · increased-permeability pulmonary edema · increased-permeability pulmonary oedema · non-cardiogenic pulmonary edema · non-cardiogenic pulmonary oedema · shock lung · Stiff lung

Data availability: 8 GWAS associations (6 studies).

Disease family

An umbrella term covering 2 Mondo subtypes.

Classification path: disease › human disease › acute disease › acute respiratory failure › acute respiratory distress syndrome

Related subtypes (2): neonatal respiratory failure, pulmonary edema

Subtypes (2): adult acute respiratory distress syndrome, pediatric acute respiratory distress syndrome

Genetics & variants

GWAS landscape

8 GWAS associations across 6 studies. Top hits map to 6 distinct genes (as reported by GWAS).

Top associations by p-value

rsID	p-value	Gene	Risk allele	Odds ratio
rs11195238	4e-08	SMC3 - Y_RNA	C	1.67
rs9508032	5e-08	FLT1	C	1.64
rs7967111	7e-08	BORCS5	G	1.35
rs619652	2e-07	CHRM3	G	1.86
rs116066418	2e-07	ANKRD31 - HMGCR	A	2.09
rs59685452	3e-06	OSTCP1, OSTCP1	C	1.84
rs11111647	3e-06	LINC02401	A	1.32

Top studies (by case count)

Study	Lead author	Year	Cases	Controls	Title
GCST012418	Du M	2021	1,250	1,583	Integrative omics provide biological and clinical insights into acute respiratory distress syndrome.
GCST90473721	UK Biobank Whole-Genome Sequencing Consortium	2025	408	458,032	Whole-genome sequencing of 490,640 UK Biobank participants.
GCST90700332	Guillen-Guio B	2025	395	1,150	Genome-wide association study of susceptibility to acute respiratory distress syndrome.
GCST010680	Guillen-Guio B	2020	274	0	Sepsis-associated acute respiratory distress syndrome in individuals of European ancestry: a genome-wide association study.
GCST005805	Bime C	2018	232	0	Genome Wide Association Study in African Americans with Acute Respiratory Distress Syndrome Identifies the Selectin P Ligand Gene as a Risk Factor.
GCST90093314	Xu JY	2021	70	0	Nucleotide polymorphism in ARDS outcome: a whole exome sequencing association study.

Variant details and genetic-evidence tiers

Tier distribution (top 50 variants)

Tier	Variants
Tier 1: coding	0
Tier 2: splice/UTR	0
Tier 3: regulatory	0
Tier 4: intronic/intergenic	7

MAF distribution

Bucket	Variants
common (>=0.05)	7
low_freq (0.01-0.05)	0
rare (<0.01)	0
unknown	0

Functional consequences

Consequence	Count
intron_variant	5
intergenic_variant	2

Top variants

rsID	Chr	Pos	Alleles	MAF	Consequence	Gene	p-value	Tier
rs11195238	10	110629099	C>A,T	0.13	intergenic_variant	SMC3 - Y_RNA	4e-08	Tier 4: intronic/intergenic
rs9508032	13	28421803	C>T	0.25	intron_variant	FLT1	5e-08	Tier 4: intronic/intergenic
rs7967111	12	12449019	G>A,C	0.444	intron_variant	BORCS5	7e-08	Tier 4: intronic/intergenic
rs619652	1	239828684	G>A,C,T	0.402	intron_variant	CHRM3	2e-07	Tier 4: intronic/intergenic
rs116066418	5	75293073	T>A	0.05	intergenic_variant	ANKRD31 - HMGCR	2e-07	Tier 4: intronic/intergenic
rs59685452	6	158856014	G>C,T	0.05	intron_variant	OSTCP1, OSTCP1	3e-06	Tier 4: intronic/intergenic
rs11111647	12	103551446	G>A	0.05	intron_variant	LINC02401	3e-06	Tier 4: intronic/intergenic

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 0 · Orphanet: 4 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

Orphanet rare-disease linkage (cohort genes)

Gene	Orphanet ID	Rare disease
CHRM3	Orphanet:2970	Prune belly syndrome
SMC3	Orphanet:199	Cornelia de Lange syndrome
RBM20	Orphanet:154	Familial isolated dilated cardiomyopathy
FLT1	Orphanet:275555	Preeclampsia

Cohort genes → proteins

5 cohort genes, 5 distinct canonical proteins.

Evidence partition

Subset	Genes
gwas_only	5

Cohort genes (full)

Symbol	HGNC	Ensembl	UniProt	Name	Evidence
BORCS5	HGNC:17950	ENSG00000165714	Q969J3	BLOC-1-related complex subunit 5	gwas
CHRM3	HGNC:1952	ENSG00000133019	P20309	Muscarinic acetylcholine receptor M3	gwas
SMC3	HGNC:2468	ENSG00000108055	Q9UQE7	Structural maintenance of chromosomes protein 3	gwas
RBM20	HGNC:27424	ENSG00000203867	Q5T481	RNA-binding protein 20	gwas
FLT1	HGNC:3763	ENSG00000102755	P17948	Vascular endothelial growth factor receptor 1	gwas

Cohort function summary

Lead sentence per gene, UniProt-curated.

Symbol	Protein name	Function (lead sentence)
BORCS5	BLOC-1-related complex subunit 5	As part of the BORC complex may play a role in lysosomes movement and localization at the cell periphery.
CHRM3	Muscarinic acetylcholine receptor M3	The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins.
SMC3	Structural maintenance of chromosomes protein 3	Central component of cohesin, a complex required for chromosome cohesion during the cell cycle.
RBM20	RNA-binding protein 20	RNA-binding protein that acts as a regulator of mRNA splicing of a subset of genes encoding key structural proteins involved in cardiac development, such as TTN (Titin), CACNA1C, CAMK2D or PDLIM5/ENH.
FLT1	Vascular endothelial growth factor receptor 1	Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFA, VEGFB and PGF, and plays an essential role in the development of embryonic vasculature, the regulation of angiogenesis, cell survival, cell migration, macrophage funct…

Protein-family classification

Druggable: 2 · Difficult: 1 · Unknown: 2 · Druggable fraction: 0.4

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

Family	Genes	Fold	FDR
Kinase	1	5.5×	0.384
GPCR	1	4.8×	0.384
Transcription factor	1	1.6×	0.634
Other/Unknown	2	0.7×	0.877

Per-gene assignment

Symbol	Family	Druggable?	EC	InterPro (top 3)
BORCS5	Other/Unknown	no		TBORCS5
CHRM3	GPCR	yes		GPCR_Rhodpsn, Musac_Ach_rcpt, Musac_Ach_M3_rcpt
SMC3	Other/Unknown	no		RecF/RecN/SMC_N, SMC_hinge, SMC
RBM20	Transcription factor	no		RRM_dom, Matrin/U1-C_Znf_C2H2, Matrin/U1-like-C_Znf_C2H2
FLT1	Kinase	yes	2.7.10.1	Prot_kinase_dom, Ser-Thr/Tyr_kinase_cat_dom, Tyr_kinase_rcpt_3_CS

Expression context

Cohort genes with no expression data: 0.

4 cohort genes are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

Bucket	Genes
narrow (1-5 tissues)	0
moderate (6-20)	0
broad (>20)	5
unknown	0

Top tissues across cohort

Tissue	Cohort genes
endothelial cell	2
prefrontal cortex	1
primordial germ cell in gonad	1
sural nerve	1
Brodmann (1909) area 23	1
middle temporal gyrus	1
oocyte	1
tendon of biceps brachii	1
ventricular zone	1
cardiac muscle of right atrium	1
left ventricle myocardium	1
myocardium	1
pericardium	1
placenta	1

Per-gene tissue summary (top 30)

Symbol	Bgee breadth	FANTOM5 breadth	SCXA	Top tissues
BORCS5	139	ubiquitous	yes	sural nerve, primordial germ cell in gonad, prefrontal cortex
CHRM3	222	broad	marker	endothelial cell, Brodmann (1909) area 23, middle temporal gyrus
SMC3	276	ubiquitous	marker	tendon of biceps brachii, ventricular zone, oocyte
RBM20	191	broad	marker	left ventricle myocardium, cardiac muscle of right atrium, myocardium
FLT1	277	broad	marker	pericardium, placenta, endothelial cell

Protein interactions among cohort

Intra-cohort edges: 0.

Hub genes (top 10 by interactor count)

Symbol	Interactor count
SMC3	5,056
RBM20	1,225
CHRM3	1,178
BORCS5	588
FLT1	261

Structural data

PDB: 3 · AlphaFold-only: 2 · No structure: 0

Cohort genes with PDB structures (top 30)

Symbol	UniProt	PDB entries
SMC3	Q9UQE7	12
FLT1	P17948	12
CHRM3	P20309	5

AlphaFold-only cohort genes (top 30 by pLDDT)

Symbol	UniProt	pLDDT
BORCS5	Q969J3	80.54
RBM20	Q5T481	48.52

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 37. Enrichment computed across 5 evidence-associated genes (3 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 3 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

Pathway	Cohort genes	Fold	FDR	Sample cohort genes
Neuropilin interactions with VEGF and VEGFR	1	951.7×	0.015	FLT1
Muscarinic acetylcholine receptors	1	761.3×	0.015	CHRM3
Mitotic Telophase/Cytokinesis	1	475.8×	0.015	SMC3
VEGF binds to VEGFR leading to receptor dimerization	1	423.0×	0.015	FLT1
Cohesin Loading onto Chromatin	1	380.7×	0.015	SMC3
Acetylcholine regulates insulin secretion	1	380.7×	0.015	CHRM3
Establishment of Sister Chromatid Cohesion	1	346.1×	0.015	SMC3
Amine ligand-binding receptors	1	115.3×	0.040	CHRM3
Meiosis	1	95.2×	0.043	SMC3
Regulation of insulin secretion	1	73.2×	0.045	CHRM3
Reproduction	1	63.4×	0.045	SMC3
S Phase	1	60.4×	0.045	SMC3
SUMO E3 ligases SUMOylate target proteins	1	59.5×	0.045	SMC3
Integration of energy metabolism	1	58.6×	0.045	CHRM3
SUMOylation	1	54.4×	0.045	SMC3
SUMOylation of DNA damage response and repair proteins	1	48.8×	0.046	SMC3
Meiotic synapsis	1	47.0×	0.046	SMC3
ESR-mediated signaling	1	42.8×	0.048	SMC3
Signaling by Nuclear Receptors	1	34.0×	0.052	SMC3
Mitotic Metaphase and Anaphase	1	32.3×	0.052	SMC3
Mitotic Anaphase	1	32.3×	0.052	SMC3
Signal Transduction	2	6.8×	0.052	CHRM3, SMC3
Resolution of Sister Chromatid Cohesion	1	28.8×	0.055	SMC3
Estrogen-dependent gene expression	1	25.2×	0.059	SMC3
Class A/1 (Rhodopsin-like receptors)	1	24.7×	0.059	CHRM3
Mitotic Prometaphase	1	23.1×	0.061	SMC3
M Phase	1	22.0×	0.061	SMC3
GPCR ligand binding	1	21.4×	0.061	CHRM3
Separation of Sister Chromatids	1	20.2×	0.062	SMC3
G alpha (q) signalling events	1	19.1×	0.063	CHRM3

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 5 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO term	Cohort genes	Fold	FDR	Sample cohort genes
vascular endothelial growth factor receptor-1 signaling pathway	1	3370.4×	0.012	FLT1
positive regulation of anterograde synaptic vesicle transport	1	1685.2×	0.012	BORCS5
establishment of meiotic sister chromatid cohesion	1	842.6×	0.012	SMC3
heart formation	1	674.1×	0.012	RBM20
spliceosome-depend formation of circular RNA	1	674.1×	0.012	RBM20
negative regulation of vascular endothelial cell proliferation	1	674.1×	0.012	FLT1
establishment of mitotic sister chromatid cohesion	1	481.5×	0.012	SMC3
hyaloid vascular plexus regression	1	481.5×	0.012	FLT1
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathway	1	421.3×	0.012	CHRM3
phospholipase C-activating G protein-coupled acetylcholine receptor signaling pathway	1	421.3×	0.012	CHRM3
saliva secretion	1	421.3×	0.012	CHRM3
regulation of lysosome size	1	374.5×	0.012	BORCS5
ligand-gated ion channel signaling pathway	1	374.5×	0.012	CHRM3
embryonic morphogenesis	1	306.4×	0.013	FLT1
regulation of endosome size	1	306.4×	0.013	BORCS5
regulation of smooth muscle contraction	1	240.7×	0.014	CHRM3
organelle transport along microtubule	1	240.7×	0.014	BORCS5
mitotic sister chromatid cohesion	1	224.7×	0.014	SMC3
G protein-coupled acetylcholine receptor signaling pathway	1	210.7×	0.014	CHRM3
positive regulation of RNA splicing	1	210.7×	0.014	RBM20
nervous system development	2	18.4×	0.014	BORCS5, CHRM3
positive regulation of smooth muscle contraction	1	187.2×	0.014	CHRM3
regulation of mRNA splicing, via spliceosome	1	177.4×	0.014	RBM20
smooth muscle contraction	1	160.5×	0.014	CHRM3
blood vessel morphogenesis	1	160.5×	0.014	FLT1
sister chromatid cohesion	1	153.2×	0.014	SMC3
negative regulation of mRNA splicing, via spliceosome	1	153.2×	0.014	RBM20
positive regulation of MAP kinase activity	1	129.6×	0.016	FLT1
acetylcholine receptor signaling pathway	1	124.8×	0.017	CHRM3
monocyte chemotaxis	1	116.2×	0.017	FLT1

Therapeutics

Drugs indicated for this disease

2 approved, 18 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Beractant	Approved (phase 4)
Poractant Alfa	Approved (phase 4)
Alteplase	Phase 3 (in late-stage trials)
Betamethasone	Phase 3 (in late-stage trials)
Dexamethasone	Phase 3 (in late-stage trials)
Dornase Alfa	Phase 3 (in late-stage trials)
Esmolol	Phase 3 (in late-stage trials)
Fospropofol	Phase 3 (in late-stage trials)
Hydroxychloroquine	Phase 3 (in late-stage trials)
Ibuprofen	Phase 3 (in late-stage trials)
Methylprednisolone	Phase 3 (in late-stage trials)
Metoprolol	Phase 3 (in late-stage trials)
Nitric Oxide	Phase 3 (in late-stage trials)
Oxygen	Phase 3 (in late-stage trials)
Pirfenidone	Phase 3 (in late-stage trials)
Propofol	Phase 3 (in late-stage trials)
Protirelin	Phase 3 (in late-stage trials)
Ravulizumab	Phase 3 (in late-stage trials)
Remestemcel-L	Phase 3 (in late-stage trials)
Sevoflurane	Phase 3 (in late-stage trials)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Adenosine, Anakinra, Aspirin, Aviptadil, Budesonide, Carbon Monoxide, Formoterol, Ginger, Isoflurane, Ketamine, Lactose, Anhydrous, Losartan, Lucinactant, Naltrexone, Remdesivir, Sodium Chloride, Soybean Oil, Tocilizumab, Ulinastatin.

Drug target analysis

Approved (phase 4): 2 · Phase ≥3: 2 · Phased (≥1): 3 · Undrugged: 2

Druggability breadth: 3 of 5 evidence-associated genes (60%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Genes with an approved drug

The molecule shown is one approved compound that hits the gene — not necessarily a drug of choice or one indicated for this disease.

Symbol	Example approved molecule
CHRM3	CARBACHOL
FLT1	PONATINIB

Top cohort targets by molecule count

Symbol	Molecules	Max phase
CHRM3	207	4
FLT1	77	4
SMC3	1	2
BORCS5	0	0
RBM20	0	0

Drugs targeting cohort genes (top 30)

Molecule	Max phase	Targets in cohort
CARBACHOL	4	CHRM3
BETHANECHOL	4	CHRM3
CLOZAPINE	4	CHRM3
ATROPINE	4	CHRM3
HALOPERIDOL	4	CHRM3
OLANZAPINE	4	CHRM3
QUETIAPINE	4	CHRM3
RISPERIDONE	4	CHRM3
CARBAMOYLCHOLINE	4	CHRM3
PIRENZEPINE	4	CHRM3
BEPRIDIL	4	CHRM3
CANDESARTAN CILEXETIL	4	CHRM3
CLOTRIMAZOLE	4	CHRM3
PROPIVERINE	4	CHRM3
VALPROIC ACID	4	CHRM3
TRIHEXYPHENIDYL HYDROCHLORIDE	4	CHRM3
IMIPRAMINE	4	CHRM3
BIPERIDEN	4	CHRM3
AMOXAPINE	4	CHRM3
IDARUBICIN	4	CHRM3
DICYCLOMINE	4	CHRM3
DESLORATADINE	4	CHRM3
CHLOROPROCAINE	4	CHRM3
ACETYLCHOLINE CHLORIDE	4	CHRM3
ANISOTROPINE	4	CHRM3
PALONOSETRON	4	CHRM3
ACLIDINIUM	4	CHRM3
CYCLACILLIN	4	CHRM3
DIMENHYDRINATE	4	CHRM3
TIOCONAZOLE	4	CHRM3

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 1.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

Symbol	Assays	Type breakdown
CHRM3	1,026	Binding:764, Functional:244, ADMET:17, Unclassified:1
FLT1	896	Binding:852, Functional:38, ADMET:6
SMC3	7	Binding:7

Cohort enzymes (BRENDA EC)

Symbol	EC numbers	Names
FLT1	2.7.10.1	receptor protein-tyrosine kinase

Cohort genes with high screening signal

≥100 ChEMBL assays — a studied-ness signal; see Therapeutics for approved-drug status.

Symbol	ChEMBL assays
CHRM3	1,026
FLT1	896

Pharmacogenomics

Cohort genes with a PharmGKB record: 5; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

30 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

Compound	Max phase	Cohort target (bioactivity)
CARBACHOL	4	CHRM3
BETHANECHOL	4	CHRM3
CLOZAPINE	4	CHRM3
ATROPINE	4	CHRM3
HALOPERIDOL	4	CHRM3
OLANZAPINE	4	CHRM3
QUETIAPINE	4	CHRM3
RISPERIDONE	4	CHRM3
CARBAMOYLCHOLINE	4	CHRM3
PIRENZEPINE	4	CHRM3
BEPRIDIL	4	CHRM3
CANDESARTAN CILEXETIL	4	CHRM3
CLOTRIMAZOLE	4	CHRM3
PROPIVERINE	4	CHRM3
VALPROIC ACID	4	CHRM3
TRIHEXYPHENIDYL HYDROCHLORIDE	4	CHRM3
IMIPRAMINE	4	CHRM3
BIPERIDEN	4	CHRM3
AMOXAPINE	4	CHRM3
IDARUBICIN	4	CHRM3
DICYCLOMINE	4	CHRM3
DESLORATADINE	4	CHRM3
CHLOROPROCAINE	4	CHRM3
ACETYLCHOLINE CHLORIDE	4	CHRM3
ANISOTROPINE	4	CHRM3
PALONOSETRON	4	CHRM3
ACLIDINIUM	4	CHRM3
CYCLACILLIN	4	CHRM3
DIMENHYDRINATE	4	CHRM3
TIOCONAZOLE	4	CHRM3

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

Tier	Definition	Genes	Symbols
A	Approved (phase 4 drug)	2	CHRM3, FLT1
B	Phased (≥1) drug, not yet approved	1	SMC3
C	Druggable family + PDB, no drug	0
D	Druggable family + AlphaFold only, no drug	0
E	Difficult family or no structure, no drug	2	BORCS5, RBM20

Undrugged target profiles

2 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

Symbol	ChEMBL assays	Drugged partners (top 3)
BORCS5	0	—
RBM20	0	—

Clinical trials & evidence

Clinical trials

Clinical trials: 1,068.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	775
PHASE2	101
PHASE3	63
PHASE1/PHASE2	42
PHASE1	38
PHASE4	25
PHASE2/PHASE3	16
EARLY_PHASE1	8

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06037330	PHASE4	RECRUITING	Nalbuphine in ARDS Patients After Surgery
NCT06934811	PHASE4	NOT_YET_RECRUITING	Ciprofol’s Impact on Oxygenator Function in Extracorporeal Membrane Oxygenation (ECMO) Patients
NCT07499154	PHASE4	NOT_YET_RECRUITING	Perioperative Lidocaine for Lung Protection in Infants Undergoing Cardiac Surgery
NCT00219375	PHASE4	COMPLETED	Study of Sivelestat Sodium Hydrate in Acute Lung Injury (ALI) Associated With Systemic Inflammatory Response Syndrome (SIRS) in Japan
NCT00299650	PHASE4	COMPLETED	Systematic Early Use of Neuromuscular Blocking Agents in ARDS Patients
NCT00773058	PHASE4	UNKNOWN	Effect of Treatment With Stress-Doses Glucocorticoid in Patients With Acute Respiratory Distress Syndrome (ARDS)
NCT01050699	PHASE4	COMPLETED	Sleep Intervention During Acute Lung Injury
NCT01573715	PHASE4	UNKNOWN	Effects of Neuromuscular Blocking Agents (NMBA) on the Alteration of Transpulmonary Pressures at the Early Phase of Acute Respiratory Distress Syndrome (ARDS)
NCT01600651	PHASE4	COMPLETED	Diffuse Acute Respiratory Distress Syndrome (ARDS), Recruitment Maneuver, and sRAGE (DAMAGE Study)
NCT01731795	PHASE4	COMPLETED	Efficacy Study of Dexamethasone to Treat the Acute Respiratory Distress Syndrome
NCT01763853	PHASE4	UNKNOWN	Impact of Fluid Resuscitation Therapy on Pulmonary Edema as Measured by Alveolar Fluid Clearance in Patients With Acute Respiratory Distress Syndrome (ARDS)
NCT01825304	PHASE4	UNKNOWN	The Study of Using Esophageal Pressure to Guide the PEEP Setting in Abdominal Hypertension Patients Who Undergoing Mechanical Ventilation
NCT02166853	PHASE4	COMPLETED	Effects of SEvoflurane on Gas Exchange and Inflammation in Patients With ARDS (SEGA Study)
NCT02902055	PHASE4	TERMINATED	Paediatric Ards Neuromuscular Blockade Study
NCT04014218	PHASE4	UNKNOWN	Effect of Inhalation Sedation Compared With Propofol on the Sepsis-related Acute Respiratory Distress Syndrome Course
NCT04133740	PHASE4	UNKNOWN	Oxygenation Targets in Cardiac Surgery Patients - a Before-and-after Study
NCT04335786	PHASE4	TERMINATED	Valsartan for Prevention of Acute Respiratory Distress Syndrome in Hospitalized Patients With SARS-COV-2 (COVID-19) Infection Disease
NCT04359862	PHASE4	TERMINATED	Sedation With Sevoflurane Versus Propofol in Patients With Acute Respiratory Distress Syndrome Caused by COVID19 Infection
NCT04397510	PHASE4	TERMINATED	Nebulized Heparin for the Treatment of COVID-19 Induced Lung Injury
NCT04663555	PHASE4	COMPLETED	Effect of Two Different Doses of Dexamethasone in Patients With ARDS and COVID-19
NCT04909697	PHASE4	COMPLETED	Treatment of ARDS With Sivelestat Sodium
NCT05153525	PHASE4	UNKNOWN	Continuous Infusion Versus Intermittent Boluses of Cisatracurium in the Early Management of Pediatric ARDS
NCT05364385	PHASE4	UNKNOWN	Intra-tracheal Instillation of Budesonide to Prevent Chronic Lung Disease
NCT05514483	PHASE4	UNKNOWN	5-HT3 Receptor Antagonist and Respiratory Drive in Patients With ARDS
NCT05658692	PHASE4	UNKNOWN	Platform Adaptive Embedded Trial for Acute Respiratory Distress Syndrome
NCT05075161	PHASE3	RECRUITING	Pirfenidone to Prevent Fibrosis in Ards.
NCT05354141	PHASE3	RECRUITING	Extracellular Vesicle Treatment for Acute Respiratory Distress Syndrome (ARDS) (EXTINGUISH ARDS)
NCT05497401	PHASE3	NOT_YET_RECRUITING	A Controlled Study to Evaluate the Efficacy of Allogeneic MesenCure for the Treatment of Patients With ARDS
NCT05847517	PHASE3	RECRUITING	Metoprolol in Acute Respiratory Distress Syndrome (MAIDEN)
NCT05849779	PHASE3	RECRUITING	Inhaled Sevoflurane for ARDS Prevention
NCT06013319	PHASE3	RECRUITING	Effect of Esmolol on Oxygenation Index in Patients With Acute Respiratory Distress Syndrome
NCT06066502	PHASE3	RECRUITING	Precision Ventilation vs Standard Care for Acute Respiratory Distress Syndrome
NCT06496997	PHASE2/PHASE3	RECRUITING	A Comparative Study of Glucocorticoids Efficacy in Acute Respiratory Distress Syndrome
NCT06526533	PHASE3	RECRUITING	RECOMMEND Platform Trial
NCT06640777	PHASE3	NOT_YET_RECRUITING	Efficacy and Safety of LEAF-4L6715 for Acute Respiratory Distress Syndrome
NCT06814340	PHASE3	RECRUITING	Continuous Positive Airway Pressure on Venovenous extracorporeaL Membrane Oxygenation for Acute respIratory Distress syndrOme
NCT07208591	PHASE3	RECRUITING	To Evaluate The Safety and Efficacy of STSA-1002 Injection in Patients With Acute Respiratory Distress Syndrome
NCT07317050	PHASE3	NOT_YET_RECRUITING	Clinical Trial With Aprotinin in the Acute Respiratory Distress Syndrome Treatment
NCT07342205	PHASE2/PHASE3	RECRUITING	A Study on the Treatment of Patients With Acute Lung Injury Caused by Sepsis Through Microbiota Transplantation
NCT07479043	PHASE3	NOT_YET_RECRUITING	To Evaluate the Safety and Potential Therapeutic Activity of JadiCell™, an Investigational Umbilical Cord-Derived Mesenchymal Stem Cell Therapy, in Patients Diagnosed With Acute Respiratory Distress Syndrome (ARDS).

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
CISATRACURIUM	4	9
NITRIC OXIDE	4	5
DEXMEDETOMIDINE	4	3
HYDROCORTISONE	4	3
MEROPENEM	4	3
ONDANSETRON	4	3
HYDROXYCHLOROQUINE	4	2
ILOPROST	4	2
METOPROLOL	4	2
MIDAZOLAM	4	2
PIRFENIDONE	4	2
TENECTEPLASE	4	2
ALMITRINE	4	1
ANGIOTENSIN II	4	1
APROTININ	4	1
ARGATROBAN	4	1
ASCORBIC ACID	4	1
AXATILIMAB	4	1
BETAMETHASONE	4	1
BREXANOLONE	4	1
CALFACTANT	4	1
DAPSONE	4	1
DEXAMETHASONE	4	1
DOBUTAMINE	4	1
ECULIZUMAB	4	1
ESMOLOL	4	1
FENTANYL	4	1
FLUDROCORTISONE ACETATE	4	1
FOSTAMATINIB	4	1
FOSTAMATINIB DISODIUM	4	1